Infectious Disease Daily Report: 01/18/2024

A phase 2-3, double-blind, randomized, placebo-controlled trial investigated the effect of simnotrelvir plus ritonavir in 1208 patients with mild-to-moderate COVID-19 (1). The study found that the time to sustained resolution of Covid-19 symptoms was significantly shorter in the simnotrelvir group than in the placebo group (180.1 hours vs. 216.0 hours; median difference, -35.8 hours; P = 0.006). On day 5, the decrease in viral load from baseline was greater in the simnotrelvir group than in the placebo group (mean difference -1.51 log(10) copies per milliliter). The incidence of adverse events during treatment was higher in the simnotrelvir group (29.0%) compared to the placebo group (21.6%). This study was funded by Jiangsu Simcere Pharmaceutical.

Reference

Cao B, Wang Y, Lu H, Huang C, Yang Y, Shang L, Chen Z, Jiang R, Liu Y, Lin L, Peng P, Wang F, Gong F, Hu H, Cheng C, Yao X, Ye X, Zhou H, Shen Y, Liu C, Wang C, Yi Z, Hu B, Xu J, Gu X, Shen J, Xu Y, Zhang L, Fan J, Tang R, Wang C. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. N Engl J Med. 2024 Jan 18;390(3):230-241. doi: 10.1056/NEJMoa2301425. PMID: 38231624.